Back to News
May 1, 2026 12:01 PM

Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk

Corcept Therapeutics Inc. (NASDAQ:CORT) shares are up on Friday as the company reported significant findings from its Phase 2 DAZALS study, demonstrating an 87% reduction in the risk of death for patients with amyotrophic lateral sclerosis (ALS) compared to those receiving a placebo.

Corcept DAZALS Phase 2 Data Drives CORT Stock Move

The DAZALS study revealed that patients treated with 300 mg of dazucorilant daily exhibited improved overall survival rates.

ALS, or Lou Gehrig’s disease, is a progressive, fatal neurodegenerative disease that destroys motor neurons in the brain and spinal cord, causing voluntary muscle loss, paralysis, and respiratory failure.

Read Also:

What's Behind The Jump In Corcept Therapeutics Stock?

Survival Benefit Observed Despite Missed Primary Endpoint

The commercial-stage pharmaceutical company said that although DAZALS did not meet its primary endpoint, at the end of the 24-week treatment period, patients who received ...